Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 48 of 48 entries
View as:

An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy

Phase: N/A Priority: Normal
NCT ID: NCT06270719 Org: User:
Start: 02/07/24 End: 12/31/38 Due: 12/31/39

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

Phase: N/A Priority: Normal
NCT ID: NCT00381433 Org: User:
Start: 09/30/06 End: 06/30/09 Due: 06/30/10

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Phase: N/A Priority: Normal
NCT ID: NCT03652259 Org: User:
Start: 10/27/18 End: 02/14/27 Due: 02/14/28

An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

Phase: N/A Priority: Normal
NCT ID: NCT03675126 Org: User:
Start: 12/19/18 End: 08/25/21 Due: 08/25/22

Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States

Phase: N/A Priority: Normal
NCT ID: NCT06747273 Org: User:
Start: 01/09/25 End: 03/29/30 Due: 03/29/31

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase: N/A Priority: Normal
NCT ID: NCT05096221 Org: User:
Start: 10/27/21 End: 10/25/24 Due: 10/25/25

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01566877 Org: User:
Start: 05/31/13 End: 01/31/14 Due: 01/31/15

A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)

Phase: N/A Priority: Normal
NCT ID: NCT01976091 Org: User:
Start: 02/01/15 End: 03/14/19 Due: 03/14/20

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)

Phase: N/A Priority: Normal
NCT ID: NCT03375255 Org: User:
Start: 02/05/18 End: 08/19/19 Due: 08/19/20

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase: N/A Priority: Normal
NCT ID: NCT02500381 Org: User:
Start: 09/28/16 End: 10/17/25 Due: 10/17/26

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

Phase: N/A Priority: Normal
NCT ID: NCT02530905 Org: User:
Start: 10/08/15 End: 10/03/18 Due: 10/03/19

A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

Phase: N/A Priority: Normal
NCT ID: NCT03985878 Org: User:
Start: 06/26/19 End: 08/31/22 Due: 08/31/23

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)

Phase: N/A Priority: Normal
NCT ID: NCT05906251 Org: User:
Start: 05/22/23 End: 08/31/28 Due: 08/31/29

rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

Phase: N/A Priority: Normal
NCT ID: NCT02710500 Org: User:
Start: 03/31/16 End: 07/31/19 Due: 07/31/20

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT04475926 Org: User:
Start: 04/22/21 End: 04/30/30 Due: 04/30/31

Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)

Phase: N/A Priority: Normal
NCT ID: NCT00451256 Org: User:
Start: 03/31/07 End: 03/31/09 Due: 03/31/10

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Phase: N/A Priority: Normal
NCT ID: NCT06597656 Org: User:
Start: 09/18/24 End: 08/31/26 Due: 08/31/27

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Phase: N/A Priority: Normal
NCT ID: NCT03218995 Org: User:
Start: 08/16/17 End: 03/10/21 Due: 03/10/22

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Phase: N/A Priority: Normal
NCT ID: NCT02420379 Org: User:
Start: 06/30/15 End: 12/17/18 Due: 12/17/19

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

Phase: N/A Priority: Normal
NCT ID: NCT01353027 Org: User:
Start: 05/31/10 End: 11/30/11 Due: 11/30/12

Safety Study of Single Administration Intravenous Treatment for Influenza

Phase: N/A Priority: Normal
NCT ID: NCT01375985 Org: User:
Start: 06/30/11 End: 11/30/11 Due: 11/30/12

Study of Eteplirsen in DMD Patients

Phase: N/A Priority: Normal
NCT ID: NCT02255552 Org: User:
Start: 11/17/14 End: 06/14/19 Due: 06/14/20

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT06606340 Org: User:
Start: 01/07/19 End: 12/31/33 Due: 12/31/34